



Place in Site Master File #13f

HOT-ICU newsletter – May 2020



Thank you very much for your steady commitment to the HOT-ICU trial.

Status

We are close to start including patients in Reykjavik, Iceland, and are looking very much forward to welcoming our North Atlantic colleagues to the trial.

As of today, 2773 of the planned 2928 patients have been included. Since mid-March we have systematically registered all COVID-19 positive cases, and have by now enrolled a total of 90.

Due to the COVID-19 pandemic, several sites have reported difficulties with recruitment and continuation of research activities due to shortness of staff. We hope resources will be re-allocated soon.



Department 4131 in Copenhagen recruited patient number 2728 the 18th of April marking the remaining 200 patients in the trial. For this effort they have received an award. Congratulations to the site!

The site that includes patient number 2828 will likewise be rewarded.

Top recruiters

Top recruiters in April were:

1. Basel (15) - Second time in a row number 1!
2. Aalborg (13)
3. Department 4131 (10)
4. Hillerød (9)
5. Roskilde (5)

Congratulation to all sites!

Things to highlight:

1. Please strive to screen all patients fulfilling the inclusion criteria as soon as possible after ICU admission
2. Please ensure that the specific e-mail notifications of major protocol violations are handled to secure adherence to protocol for all patients
3. The following documents have been updated:
[Co-enrolment list \(version 15.0\)](#). Co-enrolment is approved with the COVID-STEROID trial. Please print and file in Site Master File #8.

Keep up the great work!

If you have any questions, do not hesitate to send an e-mail to hot-icu@cric.nu or to contact the HOT-ICU hotline (+45 2118 2543). Please **leave a message and your phone number if the call is not answered** and we will call you back as soon as possible. Please archive this newsletter in your site master file.

**Kindest regards to all of our fantastic colleagues at all participating sites,
Thomas, Olav and Bodil**

